- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296359
Vaccination Response in Individual Monozygotic Twins
Study Overview
Status
Intervention / Treatment
Detailed Description
Asthma pathogenesis and exacerbations have been associated to multiple risk factors, particularly respiratory viruses. In children respiratory syncytial viruses (RSVs) may induce bronchiolitis, and Human Rhinoviruses (HRVs) also may induce wheezing illnesses. RSVs and HRVs are age dependent risk factors for asthma, with the influenza virus also considered a prominent risk factor in adults. The Center for Disease Control recommends influenza vaccination in asthmatics annually. Both HRV and RSV infections were detected in a pilot integrative personal omics investigation, and provided a unique temporal expression signature in the non-asthmatic subject, with the involvement of a common set of antigen and defense response genes, as well as immune related pathways. These observed patterns in addition to the results of the vaccination study will be used as a guide, to find differences in healthy versus asthmatic patients' pathway activations which will provide insights into the genes and mechanisms involved in asthma pathogenesis and immune response to influenza vaccination. The twin paradigm will allow us to control for multiple confounding factors and focus on the individual genetic and possible epigenetic variation. The investigators will be able to infer novel networks and pathways and get into the genes and mechanisms involved in asthma, flu vaccination, and individual responses, while evaluating personalized genetic risks compared to medical history in the same study.
Our primary investigation involves integrative multi-omics monitoring of individual monozygotic twins, healthy or discordant for asthma, following their flu vaccination, over a period of two annual vaccination cycles. The investigators will be collecting blood samples from monozygotic twin volunteers, for multiple time-points post influenza vaccination. The measurements will be repeated the following year after a second vaccination. Genomic sequencing will be used to evaluate the volunteer's genomic risks based on variants with known disease association. Full transcriptome (via RNA-Sequencing), proteome and metabolome profiling (via mass spectrometry) will be performed per time-point, as well as cytokine profiling. This will allow the dynamic monitoring of thousands of molecular components and their responses to vaccination, capturing both the initial innate response reaction in addition to the adaptive response and return to baseline. The study involves following responses in blood and saliva components after influenza vaccination. Two annual vaccinations will be considered, one per year for 2 years, and at 8 time points samples will be collected.
This study involves a simple blood draw, saliva collection, standard FDA-approved influenza vaccine administration and Spirometry.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Michigan
-
East Lansing, Michigan, United States, 48824
- Clinical and Translational Science Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Volunteers are eligible to participate in this study if both they and their twin sibling have agreed to participate. If after their enrollment in the study, one of the twin siblings decides to withdraw, then:
- If one sibling withdraws during Year 1, the other sibling will be allowed to continue their participation in the study and to complete the current study Year. However they will not be included in the randomly selected applicants that will continue participation in Year 2 of the study.
- If one sibling withdraws duringYear2, the other sibling will be able to conclude Year2 study activities. -
Exclusion Criteria:
- Volunteer is under18.
- Presence of any medical conditions that the study investigators believe will affect participation in the study or its results.
- Presence of a mental incapacity and/or cognitive impairment that would prevent a subject from adequately understanding, or cooperating with, the study protocol.
- Volunteers with any severe allergies (life-threatening) or that have ever had a life-threatening allergic reaction after a dose of flu vaccine, or have a known severe allergy to any part of this vaccine, will be advised not to participate.
If a potential subject has ever had Guillain-Barré Syndrome (a severe paralyzing illness, also called GBS), they will be advised not to get the influenza vaccine and be excluded from this study.
- For female participants If they are already enrolled and become pregnant during this study, the investigators will temporarily withdraw them from the study from the day they become pregnant. If they would like to stay in the study, the investigators may continue their participation after their delivery.
- If participants are not feeling well on the scheduled day of vaccination the investigators will suggest that they postpone the vaccination until they feel better. If they agree, the vaccination will be re-scheduled for a later date.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Asthma Discordant Monozygotic Twins
This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic.
Influenza Vaccination will be performed for both cohorts.
|
The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
|
Non-Asthma Concordant Monozygotic Twins
This is a group where both of the monozygotic twins are non-asthmatic.
Influenza Vaccination will be performed for both cohorts.
|
The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Integrated Omics profile
Time Frame: all time points (8 per year for 2 years per subject)
|
The study will construct RNA-expression, protein profiles and small molecule profiles on immune cells as these change over time prior to and following immune activation by the vaccine.
The collective temporal patterns will be used to classify immune response
|
all time points (8 per year for 2 years per subject)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: George Mias, PhD, Michigan State University
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 14-848FM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Johann Wolfgang Goethe University HospitalCompletedExercise-induced AsthmaGermany
Clinical Trials on Influenza Vaccination
-
Fondazione Policlinico Universitario Agostino Gemelli...Completed
-
Assistance Publique - Hôpitaux de ParisCompletedCystic Fibrosis With Gastrointestinal ManifestationFrance
-
Korea University Guro HospitalCompletedPneumococcal Infections | Influenza, HumanKorea, Republic of
-
Radboud University Medical CenterCompletedChronic Fatigue Syndrome | Postcancer FatigueNetherlands
-
University of Colorado, DenverSeattle Children's Hospital; Agency for Healthcare Research and Quality (AHRQ)Not yet recruiting
-
University Hospital, SaarlandKlinikum WormsCompletedCoverage Rate of Vaccination for Influenza
-
University Medical Center GroningenZonMw: The Netherlands Organisation for Health Research and DevelopmentUnknown
-
University of California, Los AngelesUniversity of Rochester; Agency for Healthcare Research and Quality (AHRQ)CompletedChildhood Influenza Vaccination | School-located Influenza Vaccination
-
Louisiana State University Health Sciences Center...Centers for Disease Control and PreventionUnknownHigh Risk for Serious Influenza | High Risk for PneumoniaUnited States
-
Jesús Moreno FernándezCastilla-La Mancha Health Service; University of Castilla-La ManchaCompletedType 1 Diabetes MellitusSpain